- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Glenmark USA launches Eribulin Mesylate Injection, a generic equivalent to Halaven, tapping into a ~$66.3 million annual market. This marks their first complex generic, boosting their institutional channel portfolio.